1,926
Views
9
CrossRef citations to date
0
Altmetric
Research Paper

Down-regulation of microRNA-125b-2-3p is a risk factor for a poor prognosis in hepatocellular carcinoma

, , , , , , , , & show all
Pages 1627-1641 | Received 29 Jan 2021, Accepted 20 Apr 2021, Published online: 05 May 2021

References

  • He L, Fan X, Li Y, et al. Overexpression of zinc finger protein 384 (ZNF 384), a poor prognostic predictor, promotes cell growth by upregulating the expression of Cyclin D1 in Hepatocellular carcinoma. Cell Death Dis. 2019 Jun 5;10(6):444.
  • Liu Y, Li H, Ye N, et al. Non-Cirrhotic liver is associated with poor prognosis of hepatocellular carcinoma: a literature review. Med Sci Monit. 2019 Sep 3;25:6615–6623.
  • Rui T, Xu S, Zhang X, et al. The chromosome 19 microRNA cluster, regulated by promoter hypomethylation, is associated with tumour burden and poor prognosis in patients with hepatocellular carcinoma. J Cell Physiol. 2020 Sep;235(9):6103–6112.
  • Zhao Y, Zhao E, Zhang J, et al. A comprehensive evaluation of the association between polymorphisms in XRCC1, ERCC2, and XRCC3 and prognosis in hepatocellular carcinoma: a meta-analysis. J Oncol. 2019;2019:2408946.
  • Wu H, Wang MD, Liang L, et al. Nanotechnology for hepatocellular carcinoma: from surveillance, diagnosis to management. Small. 2021 Jan 15;17(6):e2005236.
  • Santhakumar C, Gane EJ, Liu K, et al. Current perspectives on the tumor microenvironment in hepatocellular carcinoma. Hepatol Int. 2020 Dec;14(6):947–957.
  • Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2021. CA Cancer J Clin. 2021 Jan;71(1):7–33.
  • Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016 Mar-Apr;66(2):115–132.
  • Yao L, Zhou Y, Sui Z, et al. HBV-encoded miR-2 functions as an oncogene by downregulating TRIM35 but upregulating RAN in liver cancer cells. EBioMedicine. 2019 Oct;48:117–129.
  • Wang G, Wang Q, Liang N, et al. Oncogenic driver genes and tumor microenvironment determine the type of liver cancer. Cell Death Dis. 2020 May 4;11(5):313.
  • Li T, Li H, Wang A, et al. Development and validation of a simple model for detection of early hepatocellular carcinoma in a liver cirrhosis cohort. Cancer Manag Res. 2019;11:9379–9386.
  • Zhang W, Liu Y, Liang B, et al. Probabilistic risk assessment of dietary exposure to aflatoxin B1 in Guangzhou, China. Sci Rep. 2020 May 14;10(1):7973.
  • Chang H, Li J, Qu K, et al. CRIF1 overexpression facilitates tumor growth and metastasis through inducing ROS/NFκB pathway in hepatocellular carcinoma. Cell Death Dis. 2020 May 7;11(5):332.
  • Dong H, Jian P, Yu M, et al. Silencing of long noncoding RNA LEF1-AS1 prevents the progression of hepatocellular carcinoma via the crosstalk with microRNA-136-5p/WNK1. J Cell Physiol. 2020 Oct;235(10):6548–6562.
  • Ren Z, Chen X, Hong L, et al. Nanoparticle conjugation of ginsenoside Rg3 inhibits hepatocellular carcinoma development and metastasis. Small. 2020 Jan;16(2):e1905233.
  • Zhou Y, Huan L, Wu Y, et al. LncRNA ID2-AS1 suppresses tumor metastasis by activating the HDAC8/ID2 pathway in hepatocellular carcinoma. Cancer Lett. 2020 Jan 28;469:399–409.
  • Wu H, Zhang W, Wu Z, et al. miR-29c-3p regulates DNMT3B and LATS1 methylation to inhibit tumor progression in hepatocellular carcinoma. Cell Death Dis. 2019 Jan 18;10(2):48.
  • Liu Z, Li W, Pang Y, et al. SF3B4 is regulated by microRNA-133b and promotes cell proliferation and metastasis in hepatocellular carcinoma. EBioMedicine. 2018 Dec;38:57–68.
  • Huang WT, Liu AG, Cai KT, et al. Exploration and validation of downregulated microRNA-199a-3p, downstream messenger RNA targets and transcriptional regulation in osteosarcoma. Am J Transl Res. 2019;11(12):7538–7554.
  • Tang W, Li GS, Li JD, et al. The role of upregulated miR-375 expression in breast cancer: an in vitro and in silico study. Pathol Res Pract. 2020 Jan;216(1):152754.
  • Chen ZM, Yu Q, Chen G, et al. MiR-193a-3p inhibits pancreatic ductal adenocarcinoma cell proliferation by targeting CCND1. Cancer Manag Res. 2019;11:4825–4837.
  • Wang H, Lin X, Liu E, et al. MicroRNA-33b regulates hepatocellular carcinoma cell proliferation, apoptosis, and mobility via targeting Fli-1-mediated Notch1 pathway. J Cell Physiol. 2020 Oct;235(10):7635–7644.
  • Wu HY, Cai KT, Ma J, et al. Evaluation of miR-302b-5p expression and molecular mechanism in hepatocellular carcinoma: findings based on RT-qPCR and in silico analysis. Pathol Res Pract. 2019 Jul;215(7):152424.
  • Chen YJ, Guo YN, Shi K, et al. Down-regulation of microRNA-144-3p and its clinical value in non-small cell lung cancer: a comprehensive analysis based on microarray, miRNA-sequencing, and quantitative real-time PCR data. Respir Res. 2019 Mar 4;20(1):48.
  • Guo YN, Dong H, Ma FC, et al. The clinicopathological significance of decreased miR-125b-5p in hepatocellular carcinoma: evidence based on RT-qPCR, microRNA-microarray, and microRNA-sequencing. Int J Clin Exp Pathol. 2019;12(1):21–39.
  • Xie ZC, Huang JC, Zhang LJ, et al. Exploration of the diagnostic value and molecular mechanism of miR1 in prostate cancer: a study based on metaanalyses and bioinformatics. Mol Med Rep. 2018 Dec;18(6):5630–5646.
  • Li MF, Zeng JJ, Pan AP, et al. Investigation of miR-490-3p expression in hepatocellular carcinoma based on reverse transcription-polymerase Chain reaction (RT-qPCR) and a meta-analysis of 749 cases. Med Sci Monit. 2018 Jul 15;24:4914–4925.
  • Lu JH, Zuo ZX, Wang W, et al. A two-microRNA-based signature predicts first-line chemotherapy outcomes in advanced colorectal cancer patients. Cell Death Discov. 2018;4:116.
  • Shi J, Ye G, Zhao G, et al. Coordinative control of G2/M phase of the cell cycle by non-coding RNAs in hepatocellular carcinoma. PeerJ. 2018;6:e5787.
  • He RQ, Yang X, Liang L, et al. MicroRNA-124-3p expression and its prospective functional pathways in hepatocellular carcinoma: a quantitative polymerase chain reaction, gene expression omnibus and bioinformatics study. Oncol Lett. 2018 Apr;15(4):5517–5532.
  • Gao L, Xiong DD, He RQ, et al. Identifying TF-miRNA-mRNA regulatory modules in nitidine chloride treated HCC xenograft of nude mice. Am J Transl Res. 2019;11(12):7503–7522.
  • Gao L, Xiong DD, He RQ, et al. MIR22HG as a tumor suppressive lncRNA in HCC: a comprehensive analysis integrating RT-qPCR, mRNA-Seq, and microarrays. Onco Targets Ther. 2019;12:9827–9848.
  • Xiong DD, Feng ZB, Lai ZF, et al. High throughput circRNA sequencing analysis reveals novel insights into the mechanism of nitidine chloride against hepatocellular carcinoma. Cell Death Dis. 2019 Sep 10;10(9):658.
  • Liu LM, Lin P, Yang H, et al. Gene profiling of HepG2 cells following nitidine chloride treatment: an investigation with microarray and connectivity mapping. Oncol Rep. 2019 Jun;41(6):3244–3256.
  • Liu LM, Xiong DD, Lin P, et al. DNA topoisomerase 1 and 2A function as oncogenes in liver cancer and may be direct targets of nitidine chloride. Int J Oncol. 2018 Nov;53(5):1897–1912.
  • Pang YY, Li JD, Gao L, et al. The clinical value and potential molecular mechanism of the downregulation of MAOA in hepatocellular carcinoma tissues. Cancer Med. 2020 Nov;9(21):8004–8019.
  • Dweep H, Gretz N. miRWalk2.0: a comprehensive atlas of microRNA-target interactions. Nat Methods. 2015 Aug;12(8):697.
  • Zhou Y, Zhou B, Pache L, et al. Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. Nat Commun. 2019 Apr 3;10(1):1523.
  • Uhlen M, Fagerberg L, Hallstrom BM, et al. Proteomics. Tissue-based map of the human proteome. Science. 2015 Jan 23;347(6220):1260419.
  • Uhlen M, Zhang C, Lee S, et al. A pathology atlas of the human cancer transcriptome. Science. 2017 Aug 18;357(6352):6352.
  • Dodig-Crnkovic T, Hong MG, Thomas CE, et al. Facets of individual-specific health signatures determined from longitudinal plasma proteome profiling. EBioMedicine. 2020 Jul;57:102854.
  • Jiang H, Fu Q, Song X, et al. HDGF and PRKCA upregulation is associated with a poor prognosis in patients with lung adenocarcinoma. Oncol Lett. 2019 Nov;18(5):4936–4946.
  • Fu Q, Song X, Liu Z, et al. miRomics and proteomics reveal a miR-296-3p/PRKCA/FAK/Ras/c-Myc feedback loop modulated by HDGF/DDX5/β-catenin complex in lung adenocarcinoma. Clin Cancer Res. 2017 Oct 15;23(20):6336–6350.
  • Rosenberg S, Simeonova I, Bielle F, et al. A recurrent point mutation in PRKCA is a hallmark of chordoid gliomas. Nat Commun. 2018 Jun 18;9(1):2371.
  • Guo Y, Bao Y, Ma M, et al. Clinical significance of the correlation between PLCE 1 and PRKCA in esophageal inflammation and esophageal carcinoma. Oncotarget. 2017 May 16;8(20):33285–33299.
  • Xu L, Hazard FK, Zmoos AF, et al. Genomic analysis of fibrolamellar hepatocellular carcinoma. Hum Mol Genet. 2015 Jan 1;24(1):50–63.
  • Yang MR, Zhang Y, Wu XX, et al. Critical genes of hepatocellular carcinoma revealed by network and module analysis of RNA-seq data. Eur Rev Med Pharmacol Sci. 2016 Oct;20(20):4248–4256.